William Michener

Associate

michener-william
  • JD, cum laude, Boston College Law School, 2011; Boston College Law Review, senior editor
  • BA (Economics), summa cum laude, Boston College, 2008

Qualifications

  • Massachusetts, 2011

William Michener

Associate

Will Michener is an associate in the securities and public companies group. Will focuses his practice on representing public companies in public offerings, private financings and business combinations. In addition, Will regularly advises clients on securities law compliance and governance issues. 

Experience

  • Represented Best Doctors Holdings, Inc. in its $440 million sale to Teladoc, Inc.
  • Represented the underwriters in the $56 million initial public offering for CRISPR Therapeutics AG.
  • Represented the Affiliated Managers Group, Inc. in its approximately $480 million forward equity offering.
  • Represented The Michaels Companies, Inc., a portfolio company of Bain Capital and The Blackstone Group, in two 144A bond offerings totaling $510 million, its $472 million initial public offering, and multiple secondary offerings worth an aggregate total of $2 billion.
  • Represented Party City Holdco Inc., a portfolio company of Thomas H. Lee Partners, in its $371 million initial public offering.
  • Represented Dunkin’ Brands Group, Inc., formerly a portfolio company of Bain Capital, The Carlyle Group and Thomas H. Lee Partners, in two secondary offerings totaling over $1.4 billion and the refinancing of its senior secured credit facility with a new whole-business securitization comprised of $2.6 billion in fixed rate and variable funding securitization notes.
  • Represented the underwriters in the $214 million initial public offering and the $145 million secondary offering Multi Packaging Solutions International Limited.
  • Represented Civitas Therapeutics, Inc. in its proposed initial public offering, which concluded with its $525 million sale to Acorda Therapeutics, Inc.
  • Represented Mersana Therapeutics, Inc. in its $75 million initial public offering.
  • Represented Oxford Immunotec Global PLC in its $64 million initial public offering.
  • Represented Monitor Company Group Limited Partnership in the successful 363 bankruptcy sale of its business to Deloitte.
Cookie Settings